An observational study in Vascular Ehlers-Danlos Syndrome, Vascular Ehlers Danlos Syndrome and Vascular EDS (vEDS), sponsored by Cambridge University Hospitals NHS Foundation Trust. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-28.
Sponsored by Cambridge University Hospitals NHS Foundation Trust · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 106 studies in Insulin Resistance with a site in United Kingdom — 7 open to participants now, 9 under way, none of them phase 3. Insulin Resistance · United Kingdom.
Among the 106 studies in Insulin Resistance with a site in United Kingdom, this one is the 9th largest by planned enrollment of the 11 observational ones that give a count, is one of 3 that started in 2026, is one of 11 observational ones, and was the 104th registered.
2,974 studies on the registry are indexed under Insulin Resistance; 336 are open to participants now.
Browse Insulin Resistance studies →7 of the 106 studies in Insulin Resistance with a site in United Kingdom are open now. Recruiting first, the newest first:
Imperial College London · Sites in United Kingdom
Ages 18–70
Leeds Beckett University · Sites in United Kingdom
Ages 18–40
Manchester University NHS Foundation Trust · Sites in United Kingdom
Ages 18–99
Salah Snouda · Sites in United Kingdom
Ages 18+
Prof. Valérie Mc Lin · Sites in United Kingdom, United States, Australia and 13 more countries
Ages 1 days+
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 241 Insulin Resistance studies recruiting now, 52 (22%) set no upper age limit and 157 (65%) stop at 75 or younger; 28 take children under 18; 112 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
106 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 3 · Phase 3 5 · Phase 4 6
First in 2002; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 15 is below the median of 81 across 480 observational studies indexed under Insulin Resistance.
Median enrollment 31 across the 95 interventional studies, 147 across the 11 observational. Of the 83 that completed or were terminated, 17 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 106 have an industry lead sponsor. The 10 most frequent:
Cambridge University Hospitals NHS Foundation Trust is the lead sponsor of 172 studies on the registry; 39 are open to participants now.
Cambridge University Hospitals NHS Foundation Trust has 4 studies filed under Insulin Resistance — fewer than ten, so there is no comparison to draw.
4 of the studies in Insulin Resistance with a site in United Kingdom that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07606872Salah SnoudaValidation of the Snouda Metabolic Score for Phenotyping and Guiding Reversal in Type 2 Diabetes | 2026-12 |
| NCT06463483Imperial College LondonAutomated Insulin Delivery in Adults With Advanced Kidney Disease | 2026-12-30 |
| NCT07945093King's College LondonDiabetes Insulin Self-Management Education (DIME) Web-based Application to Support People With Type 2 Diabetes (T2D) Starting Insulin in Hospital | 2027-06-09 |
| NCT07073781Leeds Beckett UniversityProbiotics, Cognition and Metabolic Health in Young Adults With Overweight or Obesity | 2027-06-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 106 studies in Insulin Resistance with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This research study will investigate whether participants with vascular Ehlers-Danlos syndrome (vEDS), a rare inherited condition, have problems with the way the participants' body stores and uses fat (adipose tissue). vEDS is caused by changes in a gene called COL3A1, which makes a protein important for the structure of many tissues. While vEDS is best known for making blood vessels fragile, there is some early evidence that it may also affect fat tissue and increase the risk of problems such as insulin resistance (where the body does not respond properly to insulin) and diabetes.
Fat tissue is important for keeping the body healthy. It stores extra energy, but it also sends signals to other organs. If fat tissue cannot expand or work properly, fat can build up in the liver or muscles instead, leading to high blood sugar, high cholesterol, and greater risk of diabetes and heart disease.
In this study, we will invite 12-17 adults with genetically confirmed vEDS to take part, along with a group of age-, sex-, and weight-matched controls without vEDS. Participants will attend a research visit at Addenbrooke's Hospital, Cambridge. Participants will have measurements of body fat distribution (using a DEXA scan), a liver scan, blood tests, and a standard oral glucose tolerance test (drinking a sugary drink with blood samples before and after). Some participants may also choose to provide a small fat biopsy under local anaesthetic to allow more detailed analysis of tissue structure.
The main aim is to see whether people with vEDS show changes in fat distribution and insulin sensitivity compared to those without vEDS.
Participants with vascular Ehlers-Danlos syndrome and BMI, age, ethnicity and gender matched controls
Inclusion Criteria:
Exclusion Criteria for those with vEDS:
Exclusion criteria for control participants
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Individuals with confirmed pathogenic or likely pathogenic mutation in COL3A1 gene and confirmed clinical diagnosis of vascular Ehlers-Danlos syndrome
Other: No intervention, observational
Control participants matched for age, gender, ethnicity and BMI
Other: No intervention, observational
There is no intervention
OGTT-derived free fatty acid suppression test in vEDS vs matched controls
To compare adipose-tissue insulin sensitivity, quantified by the oral glucose tolerance test (OGTT)-derived free fatty acid (FFA) suppression index, between adults with genetically confirmed vascular Ehlers-Danlos syndrome (vEDS) and age-, sex-, and BMI-matched controls.
Time frame: 3 years
To describe body-fat distribution (using DEXA trunk and leg fat; trunk:leg ratio) and compare profiles between groups.
To describe body-fat distribution (using DEXA trunk and leg fat; trunk:leg ratio) and compare profiles between groups.
Time frame: 3 years
To examine relationships between adipose-tissue insulin sensitivity (OGTT)-derived free fatty acid (FFA) suppression index and biomarkers, including leptin, adiponectin, leptin/adiponectin ratio, hs-CRP, and standard lipids/biochemistry.
To examine relationships between adipose-tissue insulin sensitivity (OGTT)-derived free fatty acid (FFA) suppression index and biomarkers, including leptin, adiponectin, leptin/adiponectin ratio, hs-CRP, and standard lipids/biochemistry.
Time frame: 3 years
Plan to share: Undecided
No publications or documents are linked to this record.
Started Mar 2026 (actual). Primary completion is estimated for Mar 2030, 47 months after the start.
Of 130 non-industry observational studies under Insulin Resistance, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 142. This study's planned 47 months is below that.
Counting every sponsor, half of 133 studies reached it within 53 months; a quarter within 18 and three quarters within 142.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Cambridge University Hospitals NHS Foundation Trust →